Life Science Law in Canada

Canadian patent and trademark law, biotechnology law, patented medicines (notice of compliance) regulations, food and drug law.

Author: Mala Joshi practices at Ridout & Maybee in Toronto.

Blawg Related Categories: Intellectual Property Law • Patent Law • Trademark Law • Science & Technology Law • International • North America • Canada

Recent Posts from Life Science Law in Canada

Pfizer settles Lipitor litigation with Apotex
Pfizer Inc. announced in its August 8, 2008 quarterly report filed with the SEC that it settled its Canadian litigation in July 2008, subject to certain conditions.Life Science Law in Canada, Mala Joshi Ridout &…
(PM)NOC Reg Amendments now in force
As described in an earlier post, amendments to the Patented Medicines (Notice of Compliance) Regulations came into force on June 12, 2008. The amendments, transitional provisions, and the regulatory impact analysis statement can be found…
Proposed Amendments to the PM(NOC) Regulations
Proposed amendments to the PM(NOC) Regulations and the corresponding Regulatory Analysis Impact Statement were published in Part I to the Canada Gazette on April 26, 2008. Given that the proposed amendments are intended to reaffirm…
Supreme Court of Canada dismisses Eli Lilly leave to appeal in olanzapine case
In a judgment released yesterday, the Supreme Court of Canada dismissed Eli Lilly's appeal of the Federal Court of Appeal decision which dismissed the appeal of the Trial Court's decision not to issue a prohibition…
The buzz at CIPO...
It seems that the Canadian Intellectual Property Office ("CIPO") has been abuzz with activity in the new year, most notably through a number of new initiatives:Section 45 and trade-mark opposition proceedings will apparently soon be…
Calling all entrepreneurs!-- TiEQuest 2008
The Indus Entreprenuers (TiE), is once again hosting its annual TiE Quest 2008 business venture competition. The deadline for entry is January 31, 2008. I recently had the pleasure of attending an information session at…
"Canada Vigilance"-- Health Canada draft guidance document released
Further to the October 2006 public consultations, Health Canada has published its revisions to its draft guidance document on Adverse Drug Reactions to Marketed Health Products. This initiative stems from Health Canada's desire to more…
Health Canada to share medicines safety data with EU regulatory authorities
According to the Health Canada website, effective January 2008, regulatory experts from the EU and Canada will be able to exchange confidential information pertaining to the authorization and safety of medicines. It is alleged that…
Ontario Government invests $150 million to entice biopharmaceutical investment
In an announcement yesterday, the Ontario Minister of Research and Innovation pledged $150 million to encourage research-based pharmaceutical companies to invest in the province of Ontario. The $150 million announced will be directed to create…
Big pharma spend double on promotion than on R&D: study
According to a Canadian-led study through UQAM and York University, published on January 3 in PLOS medicine, the US pharmaceutical industry is spending almost twice as much on promotion as it does on R&D, contrary…